Conditioning treatment
Treating hospital: haematologist, oncologist, and nurse
- Giving the patient lymphodepleting chemotherapy
Medical and clinical responsibility
Give the patient lymphodepleting chemotherapy
Treating hospital: haematologist, oncologist, and nurse
Prior to the administration of YESCARTA®/TECARTUS®, patients must undergo lymphodepletion. This is achieved through the administration of chemotherapy on Days -5, -4, and -3 before YESCARTA®/TECARTUS® infusion (which will be Day 0).1,2
The regimen used is not as myeloablative as that used prior to haematopoietic stem cell transplantation.³ It makes a more favourable immune environment for the CAR T cells to multiply and persist.1,3
The regimen used prior to YESCARTA®/TECARTUS® is intravenous:¹
- cyclophosphamide 500 mg/m2
- and fludarabine 30 mg/m2.
Conditioning chemotherapy is begun only once the availability of YESCARTA®/TECARTUS® therapy is confirmed through Kite Konnect® and following a health check of the patient.¹ If YESCARTA®/TECARTUS® infusion is delayed for more than 2 weeks after the patient has received lymphodepleting chemotherapy, conditioning may need to be repeated.¹
References
- Yescarta SmPC
- Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med 2017;377:2531-44.
- Jain T, et al. Use of chimeric antigen receptor T cell therapy in clinical practice for relapsed/refractory aggressive B cell non-Hodgkin lymphoma: an expert panel opinion from the American Society for Transplantation and Cellular Therapy. Biol Blood Marrow Transplant 2019;25:2305-21.
SE-YES-0023 | 09/2024
Focus on the patient
Common patient questions
Anticipating and addressing the needs and concerns of patients
Patients’ questions on conditioning treatment may include:
- How is conditioning treatment given to me?
- Where do I go for my appointment and how long does it take?
- Will I need help getting home?
- How ill will I feel after my chemotherapy?
- What can I do to minimize or cope with any side effects?
- What if I become too ill for my CAR T therapy?
Information for patients
If you would like patient-friendly information on YESCARTA®/TECARTUS® to help you to explain this treatment to patients, please Contact Us to make a request.
In addition, you may wish to provide to your patients the contact details of trusted patient groups for more information and support on CAR T therapy.*
*Kite does not endorse or make any assurances regarding the accuracy of information on CAR T therapy provided by third party organizations.
